Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Antitope, Baylor Form Cancer Cell Line Collaboration

By Drug Discovery Trends Editor | June 6, 2014

Antitope Ltd., an Abzena company, announced that it will develop a manufacturing cell line for the Baylor Institute for Immunology Research (BIIR), one of the world’s leading centers for translational immunology research, using its Composite CHO technology. BIIR is developing a range of therapeutic vaccines for the treatment of cancer and other diseases, and Antitope will develop a cell line for the production of BIIR’s novel dendritic-cell-targeting vaccine for the treatment of head and neck and cervical cancer.
 
Antitope has developed the Composite CHO technology for the generation of stable cell lines producing high yields of proteins and antibodies ready for cGMP manufacture. The current project represents another milestone in the relationship between Antitope and BIIR, initiated several years ago when Antitope applied its Composite Human Antibody technology to humanize several novel BIIR antibodies. The humanized antibodies have been an important tool for BIIR in the development of its therapeutic vaccines. 
 
Matthew Baker, CSO of the Abzena group and co-founder of Antitope, commented: “We are delighted to be working with BIIR again and to have the opportunity to help advance one of its novel therapeutic dendritic-cell-targeting vaccines towards the clinic.”
 
Gerard Zurawski, co-director of BIIR and Director of the Center for Biotechnology at BIIR, said: “We are thrilled to be continuing our working relationship with Matthew Baker and his team at Antitope on this program and we anticipate that the vaccine can now be rapidly advanced to clinical studies.”
 
Dr. Michael Ramsay, president of Baylor Research Institute, added: “As part of the Baylor Scott & White Health system, BIIR can leverage the GMP manufacturing capability of facilities in Temple, Texas– established with funding from Cancer Prevention Research Institute of Texas (CPRIT)– and our system-wide clinical trials infrastructure, to develop products for cancer patients across the globe.”
 
Date: June 6, 2014
Source: Antitope Ltd.
 

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50